ROIVANT SCIENCES LTD (ROIV) Stock Price, Quote, News and Overview
NASDAQ:ROIV - Nasdaq - BMG762791017 - Common Stock - Currency: USD
ROIV Quote, Performance and Key Statistics
10.68
-0.04 (-0.37%)
The current stock price of ROIV is 10.68 USD. In the past month the price decreased by -4.73%. In the past year, price decreased by -7.93%.
ROIV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ROIV
Company Profile
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.
Company Info
ROIVANT SCIENCES LTD
11-12 St. James's Square, Suite 1, 3rd Floor
London GB
Employees: 845
Company Website: http://roivant.com/
Investor Relations: https://investor.roivant.com/
Phone: 442074003347.0
ROIVANT SCIENCES LTD / ROIV FAQ
What is the stock price of ROIVANT SCIENCES LTD today?
The current stock price of ROIV is 10.68 USD. The price decreased by -0.37% in the last trading session.
What is the ticker symbol for ROIVANT SCIENCES LTD stock?
The exchange symbol of ROIVANT SCIENCES LTD is ROIV and it is listed on the Nasdaq exchange.
On which exchange is ROIV stock listed?
ROIV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ROIVANT SCIENCES LTD stock?
16 analysts have analysed ROIV and the average price target is 17.19 USD. This implies a price increase of 60.99% is expected in the next year compared to the current price of 10.68. Check the ROIVANT SCIENCES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ROIVANT SCIENCES LTD worth?
ROIVANT SCIENCES LTD (ROIV) has a market capitalization of 7.62B USD. This makes ROIV a Mid Cap stock.
How many employees does ROIVANT SCIENCES LTD have?
ROIVANT SCIENCES LTD (ROIV) currently has 845 employees.
What are the support and resistance levels for ROIVANT SCIENCES LTD (ROIV) stock?
ROIVANT SCIENCES LTD (ROIV) has a support level at 10.64 and a resistance level at 10.78. Check the full technical report for a detailed analysis of ROIV support and resistance levels.
Is ROIVANT SCIENCES LTD (ROIV) expected to grow?
The Revenue of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -34.63% in the next year. Check the estimates tab for more information on the ROIV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ROIVANT SCIENCES LTD (ROIV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ROIV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ROIV, evaluating the profitability, health, valuation and growth aspects
- ROIVANT SCIENCES LTD (ROIV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ROIVANT SCIENCES LTD (ROIV) Sales and EPS estimates to see what analysts future expectations are.
- ROIVANT SCIENCES LTD (ROIV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ROIVANT SCIENCES LTD (ROIV) Insider and Institutional Ownership to learn about the owners and their transactions.
- ROIVANT SCIENCES LTD (ROIV) Stock Chart to make your own analysis
- ROIVANT SCIENCES LTD (ROIV) Latest news and press-releases to stay up to date.
Does ROIVANT SCIENCES LTD (ROIV) stock pay dividends?
ROIV does not pay a dividend.
What is the Price/Earnings (PE) ratio of ROIVANT SCIENCES LTD (ROIV)?
ROIVANT SCIENCES LTD (ROIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).
What is the Short Interest ratio of ROIVANT SCIENCES LTD (ROIV) stock?
The outstanding short interest for ROIVANT SCIENCES LTD (ROIV) is 9.59% of its float. Check the ownership tab for more information on the ROIV short interest.
ROIV Technical Analysis
ROIV Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ROIV. ROIV has a great financial health rating, but its profitability evaluates not so good.
ROIV Financial Highlights
Over the last trailing twelve months ROIV reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS increased by 88.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.01% | ||
| ROE | -2.25% | ||
| Debt/Equity | 0 |
ROIV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to ROIV. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 55.02% and a revenue growth -34.63% for ROIV